Similar articles

• Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.

  O'Brien JM, Lewis DF. O'Brien JM, et al. Am J Obstet Gynecol. 2016 Jan;214(1):45-56. doi: 10.1016/j.ajog.2015.10.934. Epub 2015 Nov 10. Am J Obstet Gynecol. 2016. PMID: 26558340 Review.
• Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.

  Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR). Manuck TA, et al. Am J Obstet Gynecol. 2016 Mar;214(3):376.e1-8. doi: 10.1016/j.ajog.2015.12.010. Epub 2015 Dec 12. Am J Obstet Gynecol. 2016. PMID: 26692181 Free PMC article.
• 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?

  Manuck TA. Manuck TA. Semin Perinatol. 2017 Dec;41(8):461-467. doi: 10.1053/j.semperi.2017.08.004. Epub 2017 Sep 22. Semin Perinatol. 2017. PMID: 28947068 Review.
• What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?

  Hall NR. Hall NR. Obstet Gynecol Clin North Am. 2011 Jun;38(2):235-46, ix-x. doi: 10.1016/j.ogc.2011.02.014. Obstet Gynecol Clin North Am. 2011. PMID: 21575799 Review.
• Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?

  Romero R, Conde-Agudelo A. Romero R, et al. BJOG. 2015 Jan;122(1):6-7. doi: 10.1111/1471-0528.13066. Epub 2014 Oct 3. BJOG. 2015. PMID: 25280114 No abstract available.